Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Log out
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Complications

Amelioration of Long-Term Renal Changes in Obese Type 2 Diabetic Mice by a Neutralizing Vascular Endothelial Growth Factor Antibody

  1. Allan Flyvbjerg1,
  2. Frederik Dagnæs-Hansen2,
  3. An S. De Vriese3,
  4. Bieke F. Schrijvers13,
  5. Ronald G. Tilton4 and
  6. Ruth Rasch5
  1. 1Medical Department M and Medical Research Laboratories, Institute of Experimental Clinical Research, Aarhus University Hospital, Aarhus, Denmark
  2. 2Department of Medical Microbiology and Immunology, University of Aarhus, Aarhus, Denmark
  3. 3Renal Unit, Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium
  4. 4Department of Pharmacology, Texas Biotechnology Corporation, Houston, Texas
  5. 5Department of Cell Biology, Institute of Anatomy, Aarhus University, Aarhus, Denmark
    Diabetes 2002 Oct; 51(10): 3090-3094. https://doi.org/10.2337/diabetes.51.10.3090
    PreviousNext
    • Article
    • Figures & Tables
    • Info & Metrics
    • PDF
    Loading

    Article Figures & Tables

    Figures

    • Tables
    • FIG. 1.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 1.

      Mean right kidney weight and glomerular volume on day 60 in nondiabetic controls (□), placebo-treated diabetic db/db mice (▪), and VEGF antibody-treated diabetic db/db mice ([cjs2108]). Values are means + SE (n = 6–12 in each group). *P < 0.01 vs. nondiabetic controls; ΔP < 0.05 vs. nondiabetic controls and placebo-treated db/db mice.

    • FIG. 2.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 2.

      BMT and total mesangial volume on day 60 in nondiabetic controls (□), placebo-treated diabetic db/db mice (▪), and VEGF antibody-treated diabetic db/db mice ([cjs2108]). Values are means + SE (n = 6–12 in each group). *P < 0.05 vs. nondiabetic controls and VEGF antibody-treated diabetic db/db mice.

    • FIG. 3.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 3.

      Mean 24-h UAE and CrCl on day 60 in nondiabetic controls (□), placebo-treated diabetic db/db mice (▪), and VEGF antibody-treated diabetic db/db mice ([cjs2108]). Values are means + SE (n = 6–12 in each group). *P < 0.01 vs. nondiabetic controls; ΔP < 0.05 vs. nondiabetic controls and placebo-treated db/db mice.

    Tables

    • Figures
    • TABLE 1

      Mean body weight, blood glucose, and food consumption at day 0 and 60 in placebo-treated controls, placebo-treated diabetic db/db mice, and VEGF antibody-treated diabetic db/db mice

      Day 0
      Day 60
      Body weight (g)Blood glucose (mmol/l)Food consumption (g/24 h)Body weight (g)Blood glucose (mmol/l)Food consumption (g/24 h)
      Control, placebo19.6 ± 0.45.4 ± 0.35.5 ± 0.621.3 ± 0.25.5 ± 0.35.9 ± 0.8
      Diabetic, placebo41.4 ± 0.7*18.6 ± 1.0*8.5 ± 0.7*47.3 ± 1.0*19.8 ± 1.4*9.1 ± 1.1*
      Diabetic, VEGF antibody40.6 ± 0.8*18.4 ± 1.0*8.8 ± 0.8*46.2 ± 0.9*18.8 ± 2.0*8.9 ± 0.9*
      • Data are means ± SE (n = 6–12 in each group).

      • *

        * P < 0.01 vs. nondiabetic controls.

    • TABLE 2

      Mean serum insulin, liver weight, and heart weight at day 60 in placebo-treated controls, placebo-treated diabetic db/db mice, and VEGF antibody-treated diabetic db/db mice

      Day 60
      Serum insulin (μg/l)Liver weight (mg)Heart weight (mg)
      Control, placebo2.86 ± 0.291,136 ± 36103 ± 4
      Diabetic, placebo18.82 ± 1.60*2,272 ± 88*109 ± 3
      Diabetic, VEGF antibody16.85 ± 1.67*1,891 ± 65†103 ± 3
      • Data are means ± SE (n = 6–12 in each group).

      • *

        * P < 0.01 vs. nondiabetic controls;

      • †

        † P < 0.05 vs. the two other groups.

    PreviousNext
    Back to top

    In this Issue

    October 2002, 51(10)
    • Table of Contents
    • Index by Author
    Sign up to receive current issue alerts
    View Selected Citations (0)
    Print
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for your interest in spreading the word about Diabetes.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Amelioration of Long-Term Renal Changes in Obese Type 2 Diabetic Mice by a Neutralizing Vascular Endothelial Growth Factor Antibody
    (Your Name) has forwarded a page to you from Diabetes
    (Your Name) thought you would like to see this page from the Diabetes web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Amelioration of Long-Term Renal Changes in Obese Type 2 Diabetic Mice by a Neutralizing Vascular Endothelial Growth Factor Antibody
    Allan Flyvbjerg, Frederik Dagnæs-Hansen, An S. De Vriese, Bieke F. Schrijvers, Ronald G. Tilton, Ruth Rasch
    Diabetes Oct 2002, 51 (10) 3090-3094; DOI: 10.2337/diabetes.51.10.3090

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Add to Selected Citations
    Share

    Amelioration of Long-Term Renal Changes in Obese Type 2 Diabetic Mice by a Neutralizing Vascular Endothelial Growth Factor Antibody
    Allan Flyvbjerg, Frederik Dagnæs-Hansen, An S. De Vriese, Bieke F. Schrijvers, Ronald G. Tilton, Ruth Rasch
    Diabetes Oct 2002, 51 (10) 3090-3094; DOI: 10.2337/diabetes.51.10.3090
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Abstract
      • RESEARCH DESIGN AND METHODS
      • RESULTS
      • DISCUSSION
      • Acknowledgments
      • Footnotes
      • REFERENCES
    • Figures & Tables
    • Info & Metrics
    • PDF

    Related Articles

    Cited By...

    More in this TOC Section

    • circRNA_010383 Acts as a Sponge for miR-135a, and Its Downregulated Expression Contributes to Renal Fibrosis in Diabetic Nephropathy
    • CaM Kinase II-δ Is Required for Diabetic Hyperglycemia and Retinopathy but Not Nephropathy
    • Connectivity Mapping Identifies BI-2536 as a Potential Drug to Treat Diabetic Kidney Disease
    Show more Complications

    Similar Articles

    Navigate

    • Current Issue
    • Online Ahead of Print
    • Scientific Sessions Abstracts
    • Collections
    • Archives
    • Submit
    • Subscribe
    • Email Alerts
    • RSS Feeds

    More Information

    • About the Journal
    • Instructions for Authors
    • Journal Policies
    • Reprints and Permissions
    • Advertising
    • Privacy Policy: ADA Journals
    • Copyright Notice/Public Access Policy
    • Contact Us

    Other ADA Resources

    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • Scientific Sessions Abstracts
    • Standards of Medical Care in Diabetes
    • BMJ Open - Diabetes Research & Care
    • Professional Books
    • Diabetes Forecast

     

    • DiabetesJournals.org
    • Diabetes Core Update
    • ADA's DiabetesPro
    • ADA Member Directory
    • Diabetes.org

    © 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.